Ksybiz Hyperbarics: USA DR. THIBODEAUX HYPERBARIC RESEARCH ON VIRAL SARS DUE TO COVID-19

Dr Khurrum Shaukat Yusafzai ,

Hyperbaric Medical Consultant.

CLICK TO SEE VIDEO : https://youtu.be/Ct5tX-f9_Ms

As World Faces Severe Shortage of Ventilators ,
Hyperbaric Chambers are possible Replacement of Ventilators
Proving to be Far Better than the Ventilators in many ways, in treatment of Covid-19.
Increase of Healing the Covid-19
Reduction in Inflammation
Reduction in Lymphocytes , Fibronogin , CRP and D-Dimers
Replication of Chinese Study of Similar Nature

Today I show you Covid-19 treatment via Hyperbaric Medicine in USA and race by other Countries to adopt it.

So let's begin and See my Video on You tube channel that you have to Subscribe and Press the Bell Icon for Informative Videos :

USA :

In Opelousas General Hospital under UCAS University in LA USA after Corona Spread from epicenter in China in Wuhan Hubei to Rest of World , USA was Hit Hard and it Required use of HBOT for Treating of SARS

Progressive Hypoxia of the Patients know as SARS , Severe Acute Respiratory Syndrome was treated by Hyperbaric Chambers .

Patients were not getting Better even with Mechanical Assisted Respiration with the Ventilators , and 88-90 % were dying

SARS was endangering their lives that could lead to Certain death ,

RESEARCH :

Hyperbaric Chambers Provided by Sechrist USA are being utilised as an Alternative to Ventilators in Treatment of many Diseases including SARS , Severe Acute Respiratory Distress Syndrome due to Viral Infections . Hyperbaric Chambers as Oxygenation Devices that are Classified as Class 2 Devices just like Ventilators , but far More Power full .

According to the Research Paper published , Hyperbaric Medical Clinical Research Trials of Hyperbaric Chambers as an Alternative to Ventilators as Oxygenation Devices and this Study Demonstrated that HBOT can save from Need of Ventilators where 88-90% die due to Invasive Intubation .

link to Research Article: Clinical Research Trials in Month of April

The results were Published : 2020-May-1st ,

Published Online:15 May 2020 : https://doi.org/10.12968/jowc.2020.29.Sup5a.S4

Research Led by

Dr. Kerry Thibodeaux

Specialist in wound care surgery and

Specialist in Subaquatic and Hyperbaric medicine

University chair director Hyperbaric Oxygen Therapy and UCAS University LA USA and

Opelousas General Hospital

Dr Amer Raza

Critical Care and Pulmonologist Opelousas General Hospital Marcus Sprayer Hyperbaric Medical Technician and RN Critical Care Opelousas General Hospital

Raphael Yaakov

Opelousas General Hospital

Thomas E Serena

Opelousas General Hospital

SUMMARY

Abstract

A pandemic afflicts the entire world. The highly contagious SARS-CoV-2 virus originated in Wuhan, China in late 2019 and rapidly spread across the entire globe. According to the World Health Organization (WHO), the novel Coronavirus (COVID-19)has infected more than two million people worldwide, causing over 160,000 deaths.

Patients with COVID-19 disease present with a wide array of symptoms, ranging from mild flu-like complaints to life threatening pulmonary and cardiac complications. Older people and patients with underlying disease have an increased risk of developing severe acute respiratory syndrome (SARS) requiring mechanical ventilation. Once intubated, mortality increases exponentially.

A number of pharmacologic regimens, including hydroxychloroquine-azithromycin, antiviral therapy (eg, remdesevir), and anti-IL-6 agents (e.g., toclizumab), have been highlighted by investigators over the course of the pandemic, based on the therapy's potential to interrupt the viral life-cycle of SARS-CoV-2 or preventing cytokine storm.

At present, there have been no conclusive series of reproducible randomised clinical trials demonstrating the efficacy of any one drug or therapy for COVID-19.

Method

COVID-19 positive patients (n=5) at a single institution received hyperbaric oxygen therapy (HBOT) between 13 and 20 April 2020. All the patients had tachypnoea and low oxygen saturation despite receiving high FiO2. HBOT was added to prevent the need for mechanical ventilation. A standard dive profile of 2.0ATA for 90 minutes was employed. Patients received between one and six treatments in one of two dedicated monoplace hyperbaric chambers.

Findings

All the patients recovered without the need for mechanical ventilation. Following HBOT, oxygen saturation increased, tachypnoea resolved and inflammatory markers fell. At the time of writing, three of the five patients have been discharged from the hospital and two remain in stable condition.

CONCLUSION

This small sample of patients exhibited dramatic improvement with HBOT. Most importantly, HBOT potentially prevented the need for mechanical ventilation. Larger studies are likely to define the role of HBOT in the treatment of this novel disease.

The highly contagious SARS-CoV-2 virus, thought to have originated in Wuhan, China, has infected more than two million people at the time of writing.

In the US alone, the death toll exceeds 40,000 people.The pathogenic SARS-CoV-2, a single-stranded, RNA-enveloped virus, causes respiratory disease in humans.

The clinical presentation varies from asymptomatic SARS-CoV-2 positive patients to life threatening cardiac and pulmonary complications. An article in the Journal of the American Medican Association (JAMA) in February 2020 from Wuhan, China reported that 26% of infected patients required intensive care with a mortality rate of 4.3%.

Older people and patients with multiple comorbidities have an increased risk of severe acute respiratory syndrome (SARS) and death. In addition, an elevated D-dimer (a product of fibrinogen degradation that indicates a prothrombotic state) on admission corresponds with a poor outcome.

Finally, once the patient requires mechanical ventilation, the risk of mortality rises sharply.

In the absence of effective therapy, social distancing has helped to decrease the rate of those in the general population becoming infected in an attempt to avoid overwhelming the existing healthcare infrastructures. For patients who contract the virus and develop serious respiratory disease, the solution must entail successful treatment options.

At the time of this writing, there are no US Food and Drug Administration (FDA) approved medications or therapies for COVID-19. A search of clinicaltrials.gov reveals over 300 clinical trials ongoing or preparing to enrol for COVID-19 disease.

These trials focus primarily on pharmacologic therapies based on interrupting the viral life-cycle or preventing cytokine storm and include hydroxychloroquine-azithromycin, antiviral therapy (for example, remdesevir), and anti-IL-6 agents (for example, toclizumab).

Hyperbaric oxygen treatment (HBOT) is an FDA-approved medical treatment with several indications including wound healing, late effects of radiation therapy, necrotising fasciitis, compromised flaps, carbon monoxide poisoning and air diving decompression illness.

In the hyperbaric chamber, the patient breathes 100% oxygen at 1–1.5 times atmospheric pressure. The increased pressure results in increased dissolved oxygen in the plasma and tissues. Theoretically, HBOT could address the hallmarks of severe COVID-19 disease: progressive hypoxia and pulmonary inflammation. The exact mechanism of action is unclear. However, ultra-high oxygen levels may have several antiviral effects: increasing the production of viricidal free oxygen radicals,

upregulating hypoxic inducible factor (HIF), which in turn stimulates the production of antiviral peptides such as defensins and cathelicidins, and reducing proinflammatory cytokines such as IL-6 responsible for cytokine storm.

The first reported use of HBOT in COVID-19 disease came from Wuhan, China. There were five patients who received HBOT for severe respiratory disease: two described as having critical disease and three with severe disease. The primary criteria for HBOT was impending intubation, i.e., increased oxygen requirements with falling sauration and severe tachypnoea. The rapid resolution of tachypnoea and correction of hypoxia was observed in all five patients. No complications related to the HBOT were reported.

As the disease spread to the US, physicians considered using HBOT as part of the treatment regimen for COVID-19 disease. There are no contraindications to the use of HBOT in patients with viral pneumonia or SARS. The only absolute contraindication to HBOT is an untreated pneumothorax.

Ksybiz Hyperbarics

Pages

Tuesday, July 28, 2020

USA DR. THIBODEAUX HYPERBARIC RESEARCH ON VIRAL SARS DUE TO COVID-19

USA :

RESEARCH :

SUMMARY

CONCLUSION

KSYBIZ HYPERBARIC CHANNEL

No comments:

Post a Comment